Bandingkan Harga & Kinerja Lotte Chemical Titan Tbk. (FPNI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Lotte Chemical Titan Tbk. dan Organon Pharma Indonesia Tbk.: Lotte Chemical Titan Tbk. diperdagangkan di Rp545 (kapitalisasi pasar 3,15 T, volume 24 jam 3,73 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Lotte Chemical Titan Tbk. jauh lebih besar — sekitar 30,2× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| FPNI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 3,15 T | 104,4 M |
Volume | 3,73 jt | — |
Lot | 37,31 rb | — |
Perputaran | 2,02 M | — |
Harga Rata-rata | 541,28 | — |
Nilai Transaksi | 2,02 M | — |
Harga Ekuilibrium Indikatif | 545 | — |
Volume Ekuilibrium Indikatif | 643 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Lotte Chemical Titan Tbk.
PT. Lotte Chemical Titan Tbk. (the Company) was established in the Republic of Indonesia under the name of P.T. Indofatra Plastik Industri based on Notarial Deed No. 19 of Rukmasanti Hardjasatya, S.H., dated December 9, 1987. Subsequently, its name was changed to P.T. Fatrapolindo Nusa Industri based on Notarial Deed No. 53 dated July 18, 1988 of the same notary. The Company conduct in Bi-axially Oriented Polypropylene/ BOPP Film industry. Start the commercial operation on 1990 by one line production. Now, the corporate have load capacity 20.000 ton/year.
Selengkapnya di halaman FPNI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
